Frédèric Selle
0000-0002-7016-5383
Publication & Citation Trends
Most Cited Works
Publications
292 total
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.
Cited by 8
Semantic Scholar
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group OA
Cited by 24
Semantic Scholar
A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial OA
Cited by 13
Semantic Scholar
Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial PDF
Cited by 314
OpenAlex
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. OA
Cited by 141
Semantic Scholar
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.
Cited by 7
Semantic Scholar
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial OA
Cited by 64
Semantic Scholar
34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trial OA
Cited by 16
Semantic Scholar
Research Topics
Ovarian cancer diagnosis and treatment
(201)
PARP inhibition in cancer therapy
(90)
BRCA gene mutations in cancer
(50)
Intraperitoneal and Appendiceal Malignancies
(35)
Renal cell carcinoma treatment
(32)
Frequent Co-Authors
Affiliations
Université Claude Bernard Lyon 1
Oslo University Hospital
University College Hospital
Seoul National University
Inserm